Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan:146:110441.
doi: 10.1016/j.mehy.2020.110441. Epub 2020 Nov 29.

Inhaled milrinone for sick COVID-19 cohort: A pathophysiology driven hypothesis!

Rohan Magoon  1 , ItiShri  2 , Jasvinder Kaur Kohli  2 , Ramesh Kashav  2
Affiliations
Comment

Inhaled milrinone for sick COVID-19 cohort: A pathophysiology driven hypothesis!

Rohan Magoon et al. Med Hypotheses. 2021 Jan.
No abstract available

Keywords: Acute respiratory distress syndrome; COVID-19; Endothelial dysfunction; Hypothesis; Inhaled milrinone; Pathophysiology; Systemic inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Comment on

References

    1. Magoon R. Pulmonary vasculature in COVID-19: mechanism to monitoring [ahead of print, 2020 October 5] Korean J Anesthesiol DOI: https://doi.org/10.4097/kja.20536. - PMC - PubMed
    1. Magoon R. The pulmonary circuit dynamics in COVID-19! J Anesth. 2020 doi: 10.1007/s00540-020-02869-6. [ahead of print] - DOI - PMC - PubMed
    1. Green S.J. Covid-19 accelerates endothelial dysfunction and nitric oxide deficiency. Microbes Infect. 2020;22(4-5):149–150. doi: 10.1016/j.micinf.2020.05.006. - DOI - PMC - PubMed
    1. Dalamaga M., Karampela I., Mantzoros C.S. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19. Metabolism. 2020;109:154282. doi: 10.1016/j.metabol.2020.154282. - DOI - PMC - PubMed
    1. Zuo H., Cattani-Cavalieri I., Musheshe N., Nikolaev V.O., Schmidt M. Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacol Ther. 2019;197:225–242. doi: 10.1016/j.pharmthera.2019.02.002. - DOI - PubMed